SCHEDULE: Deep Track Capital Divests Entire Invivyd Stake
Beneficial Ownership Report (Schedule 13G Amendment)
Deep Track Capital and related entities report 0% beneficial ownership of Invivyd, Inc. common stock in an amended Schedule 13G filing.
Summary
- Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have reported 0% beneficial ownership of Invivyd, Inc. common stock.
- This filing, Amendment No. 3 to Schedule 13G, indicates a complete divestment of their previous holdings in Invivyd, Inc.
- The event requiring this filing, which signifies the change in ownership, occurred on September 30, 2025.
- The calculation of beneficial ownership is based on 194,954,215 shares of Common Stock outstanding as of August 22, 2025, as per Invivyd's Prospectus.
Sentiment
Score: 3
Explanation: The complete divestment by a specialized institutional investor is generally viewed as a negative signal for the company's stock, indicating a lack of confidence or a shift in investment strategy by a knowledgeable party.
Negatives
- The complete divestment by Deep Track Capital, a specialized biotechnology investor, could be perceived as a negative signal regarding their confidence in Invivyd, Inc.'s future prospects.
Future Outlook
NA
Industry Context
This filing reflects a significant institutional investor's decision to fully exit its position in a biotechnology company. Such divestments by specialized funds can sometimes influence market perception within the biotech sector, particularly if the fund is known for its expertise in the industry.
Stakeholder Impact
- Shareholders: May react negatively to the news of a significant institutional investor's complete divestment, potentially leading to downward pressure on the stock price due to concerns about the company's future prospects or perceived lack of confidence from a sophisticated investor.
Key Dates
| Date | Description |
|---|---|
| 2025-08-22 | Date of issuer's Prospectus, stating 194,954,215 Common Stock outstanding, used for beneficial ownership calculation. |
| 2025-09-30 | Date of event which required the filing of this statement, indicating the change in beneficial ownership to 0%. |
| 2025-11-14 | Date of signing for the Schedule 13G Amendment No. 3. |
Recommendation
sellThe complete divestment by Deep Track Capital, a specialized biotech fund, suggests a significant loss of confidence or a negative outlook from an informed institutional investor. While the filing does not provide reasons, such a move typically signals underlying concerns that warrant a 'sell' recommendation for existing holders or caution for potential investors.
Keywords
Invivyd Inc, Deep Track Capital, Schedule 13G, Beneficial Ownership, Divestment, Common Stock, Biotechnology Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.